Compare Iris Energy Limited (IREN) vs TG Therapeutics Inc (TGTX) Price & Performance

IREN is trading at $35.71, down 7.7% in the last 24 hours, showing bearish technical momentum despite strong analyst support. The company reported $501M revenue in 2025 with 17.35% profit margin, but faces significant losses projected for 2026 (-$703M net income). Recent news highlights IREN's pivot from Bitcoin mining to AI infrastructure with major contracts including a $9.7B Microsoft deal, though execution risks and capital intensity remain concerns.

While Wall Street maintains bullish sentiment with an $81 consensus price target (80% buy ratings), IREN faces substantial execution risks amid aggressive expansion. The stock offers potential upside if the company successfully scales its AI infrastructure business, but current negative profitability and high valuation ratios (P/E 51.42, P/S 15.97) suggest caution for near-term investors.

TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.

The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.